Rebeccamycin

Rebeccamycin, an antitumor antibiotic, inhibits DNA topoisomerase I. Rebeccamycin appears to exert its primary antineoplastic effect by poisoning topoisomerase I and has negligible effect on protein kinase C and topoisomerase II[1][2].

Product Specifications

CAS Number

93908-02-2

UNSPSC

12352005

Target

ADC Payload; Antibiotic; Topoisomerase

Type

Natural Products

Related Pathways

Antibody-drug Conjugate/ADC Related; Anti-infection; Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rebeccamycin.html

Solubility

10 mM in DMSO

Smiles

O=C(N1)C(C2=C3N([C@@H]([C@@H]([C@@H](O)[C@@H]4OC)O)O[C@@H]4CO)C5=C2C=CC=C5Cl)=C(C(C6=CC=C7)=C3NC6=C7Cl)C1=O

Molecular Formula

C27H21Cl2N3O7

Molecular Weight

570.38

References & Citations

[1]Merchant J, et al. Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats. Clin Cancer Res. 2002 Jul;8 (7) :2193-201.|[2]Bush JA, et al. Production and biological activity of rebeccamycin, a novel antitumor agent. J Antibiot (Tokyo) . 1987 May;40 (5) :668-78.|[3]Sánchez C, et al. The biosynthetic gene cluster for the antitumor rebeccamycin: characterization and generation of indolocarbazole derivatives. Chem Biol. 2002 Apr;9 (4) :519-31.